IGF1R and breast carcinoma: A literature figured out “Drug repurposing” to be a clinical strategy through the use of approved drugs for breast cancer therapeutics [5], such as the combination of insulin like growth factor 1 receptor (IGF1R) inhibitors with approved drug Rapamycin [6] demonstrates the inhibition of breast cancer cells proliferation [7].